• user warning: Got error 28 from storage engine query: SELECT t.tid, t.* FROM term_data t INNER JOIN term_hierarchy h ON h.parent = t.tid WHERE h.tid = 14074 ORDER BY weight, name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 755.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14299 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14287 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14288 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14159 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14161 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14162 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14137 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14138 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14071 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 14069 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.

analyst

GSI Commerce Reported Mixed Q4 Results, Top Line Up 25%

Published on Wed, 02/09/2011 - 17:24
By Christie Duffy

GSI Commerce has a potential upside of 39.1% based on a current price of $22.24 and an average consensus analyst price target of $30.93.

GSI Commerce is currently below its 50-day moving average (MA) of $23.32 and below its 200-day MA of $25.10.

earnings, eps, revenue, beat, wall street, company, quarter, year, margin, income, gross, net, invest, advice, ceo, cfo, executive, market, stock, share, price, target, analyst, business, finance

GSI Commerce (NASDAQ:GSIC) reported Q4 EPS of $0.57, topping consensus estimates of $0.51 per share. Revenues for the quarter rose 25% year-over-year to $537.0 million, ahead of consensus estimates of $532.9 million.

By Christie Duffy
cduffy@fnno.com

Equinix Tops Q4 Sales and EPS Estimates

Published on Wed, 02/09/2011 - 16:40
By Christie Duffy

The company sees Q1 sales of $354-$356 million vs a Street target of $354 million. Gross margins are expected to be approximately 64%.

market, share, eps, earning, revenue, roi, return, invest, advice, analyst, ceo, executive, cfo, finance, financial, buy, sell, stock, share, market, sector, industry, quarter, year, estimate, consensus, wall street

Equinix (NASDAQ:EQIX) reported Q4 EPS of 29 cents, topping consensus estimates of 23 cents. Revenue totaled $345.2 million, inline with Street estimates.

By Christie Duffy
cduffy@fnno.com

Cisco Tops Q2 Estimates, But Shares Fall

Published on Wed, 02/09/2011 - 16:40
By Christie Duffy

Cisco reported adjusted inventory turns of 10.0 and days sales outstanding of 40 days. That is is up from 38 days during Q1.

Chairman and CEO John Chamber said, "The quarter played out as we expected. Our strategy of tightly integrating our multiple products through an architectural approach is working, and we are delivering innovation in each major pro

market, share, eps, earning, revenue, roi, return, invest, advice, analyst, ceo, executive, cfo, finance, financial, buy, sell, stock, share, market, sector, industry, quarter, year, estimate, consensus, wall street

Cisco (NASDAQ:CSCO) reported fiscal Q2 EPS of 37 cents, topping consensus estimates of 35 cents. Sales in the quarter totaled $10.41 billion, above the Street estimate of $10.24 billion.

By Christie Duffy
cduffy@fnno.com

Teva Pharmaceuticals Down 0.9% Despite Positive Results from Phase III Trial of Rhinits Drug

Published on Wed, 02/09/2011 - 13:41
By Christie Duffy

Teva said results from a Phase III study of QNAZE HFA, its nasal aerosol corticosteroid in development to treat perennial allergic rhinitis (PAR) and seasonal allergic rhinitis, achieved all primary and secondary efficacy endpoint

Teva shares are down 0.9%, or $0.46, to $51.56.

teva, pharmaceutical, pill, drug, test, trial, fda, review, government, approval, patient, cure, aid, sick, allergy, share, trade, stock, sector, industry, analyst, phase, rhinits

Teva Pharmaceuticals (TEVA) shares are down fractionally, despite positive drug trial news.

By Christie Duffy
cduffy@fnno.com

Morgan Stanley Adjusted Its 2011, 2012 EPS Estimates For OpenTable, Maintained Its EW Rating

Published on Wed, 02/09/2011 - 13:41
By Christie Duffy

The bank sees 2011 EPS of $0.77, down from $0.86 per share, and 2012 EPS of $1.28, up from $1.12 per share.

OpenTable is currently above its 50-day moving average (MA) of $75.14 and above its 200-day of $57.89.

opentable, restaurant, reservation, buy, sell, stock, trade, invest, roi, return, margin, profit, revenue, analyst, upgrade, downgrade, price, target, market, sector, industry, rating, report, research, eps, moving average, morgan stanley, NASDAQ:OPEN

Morgan Stanley adjusted its 2011 and 2012 EPS estimates for OpenTable (NASDAQ:OPEN) and maintained its equal-weight rating.

By Christie Duffy
cduffy@fnno.com

Polo Ralph Lauren Surges Nearly 9% After Reporting Q3 Results

Published on Wed, 02/09/2011 - 13:41
By Christie Duffy
polo, ralph, lauren, clothes, retail, store, buy, sell, stock, share, earn, invest, return, roi, advice, street, wall, trade, revenue, income, quarter, year, fiscal, company, firm, report, research, analyst, million, billion, dollar, cash, diluted

Polo Ralph Lauren (RL) posted net income of $168 million, or $1.72 per diluted share, for the third quarter of fiscal 2011, versus net income of $111 million, or $1.10 per diluted share, for the same period in fiscal 2010. The Str

By Christie Duffy
cduffy@fnno.com

Stratasys Shares up 11.30% on 80% Increase in Q4 Profit

Published on Wed, 02/09/2011 - 12:52
By Christie Duffy

The company posted record revenue of $33.8 million for the fourth quarter ended Dec. 31, a 29% increase over the $26.2 million reported for the same period in 2009. Net income was $4.3 million for the fourth quarter, or $0.20 per

advice, analyst, average, balance, bank, billion, business, company, down, downgrade, earnings, economy, eps, estimate, expecton billion quarter year fiscal finance business economy roi return invest advice balance sheet net income gross margin result report research analyst firm bank company stock share trade up down upgrade downgrade trend percent industry sector average, finance, firm, fiscal, gross, income, industry, invest, margin, million, net, percent, quarter, report, research, result, return, reuters, revenue, roi, sector, share, sheet, stock, trade, trend, up, upgrade, year

Shares of Stratasys (SSYS) are up $4.80 to $40.18, or 11.61%, after the company reported strong fourth quarter and full year financial results that surpassed market expectations.

By Christie Duffy
cduffy@fnno.com

Morgan Stanley Lowered Its EPS Estimates For DuPont (DD)

Published on Wed, 02/09/2011 - 12:52
By Christie Duffy
Analyst, DuPont, chemical, eps, revenue, buy, sell, analyst, firm, estimate, bank, research, invest, advice, delaware, material, manufacture, stock, market, trade, revenue, roi, dollar, share, target, price

Morgan Stanley lowered its 2011 and 2012 EPS estimates for DuPont (NYSE:DD) and maintained its equal-weight rating and $56 price target. The bank sees 2011 EPS of $3.65, down from $3.71 per share, and 2012 EPS of $4.03, down from

By Christie Duffy
cduffy@fnno.com

Morgan Stanley Lowered Its EPS Estimates For Sara Lee, Maintained Its EW Rating (SLE)

Published on Wed, 02/09/2011 - 12:22
By Christie Duffy
moving, average, stock, price, ticker, market, trade, earn, profit, net, gross, margin, analyst, action, report, upgrade, downgrade, research, advise, invest, money, cash, dollar, NYSE, SLE, NYSE:SLE, NASDAQ, food, stock, sector, morgan, stanley, bank, firm

Morgan Stanley lowered its 2011 and 2012 EPS estimates for Sara Lee (NYSE:SLE) and maintained its equal-weight rating and $14.50 price target. The bank sees 2011 EPS $0.85, down from $0.89 per share, and 2012 EPS of $1.00, down fr

By Christie Duffy
cduffy@fnno.com

Morgan Stanley Lowered its 2011, 2012 EPS Estimates For Teva Pharmaceutical Industries (TEVA)

Published on Wed, 02/09/2011 - 12:22
By Christie Duffy
teva, pharmaceutical, pills, prescription, medicine, heal, earn, buy, sell, upgrade, downgrade, share, stock, market, price, target, analyst, research, report, firm, bank, industry, sector, business, finance, invest, advice, money, dollar, million, billion, up, down, equal-weight, rating

Morgan Stanley lowered its 2011 and 2012 EPS estimates for Teva Pharmaceutical Industries (NASDAQ:TEVA) and maintained its equal-weight rating. The bank sees 2011 EPS of $5.05, down from $5.29 per share, and 2012 EPS of $5.78, do

By Christie Duffy
cduffy@fnno.com

Most Popular Video News